iCONNECT with Baxter Canada

Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen

23 min · 5. juni 2023
episode Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen cover

Beskrivelse

IV Insulin has been defined as a top-rated high-alert medication by the Institute for Safe Medication Practices, and yet options to improve the safety of these infusions have been limited until recently.  Dr. Kevin Hansen will discuss his experience using Myxredlin, a ready-to-administer insulin infusion product that has changed how many organizations manage these high-risk infusions in the US.  He will also introduce some of the concepts for consideration when organizations are exploring the introduction of ready-to-administer products including patient safety, pharmaco-economics, drug stability, human resource management, and workflows. Link to discussed publication:  https://www.pppmag.com/article/2655 [https://www.pppmag.com/article/2655]

Kommentarer

0

Vær den første til å kommentere

Registrer deg nå og bli medlem av iCONNECT with Baxter Canada sitt community!

Prøv gratis

Prøv gratis i 14 dager

99 kr / Måned etter prøveperioden. · Avslutt når som helst.

  • Eksklusive podkaster
  • 20 timer lydbøker i måneden
  • Gratis podkaster

Alle episoder

31 Episoder

episode Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen cover

Improving the Safety of High Risk Insulin Infusions with Dr. Kevin Hansen

IV Insulin has been defined as a top-rated high-alert medication by the Institute for Safe Medication Practices, and yet options to improve the safety of these infusions have been limited until recently.  Dr. Kevin Hansen will discuss his experience using Myxredlin, a ready-to-administer insulin infusion product that has changed how many organizations manage these high-risk infusions in the US.  He will also introduce some of the concepts for consideration when organizations are exploring the introduction of ready-to-administer products including patient safety, pharmaco-economics, drug stability, human resource management, and workflows. Link to discussed publication:  https://www.pppmag.com/article/2655 [https://www.pppmag.com/article/2655]

5. juni 202323 min